0.4336USD-9.48%Mkt Cap: 15.81M USDP/E: —Last update: 2026-06-01
GT Biopharma, Inc., a clinical stage biopharmaceutical company, engages in the development and commercialization of immuno-oncology products based on its Tri-specific Killer Engager (TriKE) and Tetra-specific Killer Enga…
Industry Peers
Biotechnology111.39BUSDP/E 26.0
100.62BDKKP/E 19.4
62.97BUSDP/E 14.7
48.39BEURP/E 31.7
44.65BEURP/E 37.2
40.10BUSDP/E 75.3
35.22BUSD—
32.91BSEKP/E 48.6
Indicators:|
Key Statistics
Company
Market Cap15.81M USD
Enterprise Value8.32M USD
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-28.35M USD
Revenue/Share—
Last Price0.4336 USD
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees1
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-0.04
PEG1.05
EV/EBITDA—
EV/Revenue—
P/S—
P/B2.22
EPS (TTM)-6.46
EPS (Forward)-10.80
52W Range
0.26105% of range3.850
52W High3.850 USD
52W Low0.2610 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-489.96%
ROA-349.79%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-12.91M USD
CapEx (TTM)—
FCF Margin—
FCF Yield-63.14%
Net Debt-8.92M USD
Net Debt/EBITDA—
Balance Sheet
Debt/Equity—
Current Ratio4.14
Quick Ratio3.69
Book Value/Sh0.2150 USD
Cash/Share0.2470 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay DateAug 21, 2017
Splits
Last Split1:30
Split DateFeb 5, 2024
Analyst Consensus
Rating1.0 (Strong Buy)
Target (Mean)3.000 USD
Target Range3.000 USD – 3.000 USD
# Analysts1
Ownership
Shares Out.36.06M
Float33.53M
Insiders3.42%
Institutions6.87%
Short Interest
Short Ratio1.4d
Short % Float5.76%
Short % Out.5.75%
Shares Short2.08M
Short (prev mo.)671.07K
Technical
SMA 500.3912 (+10.8%)
SMA 2000.6414 (-32.4%)
Beta0.64
S&P 52W Chg27.94%
Avg Vol (30d)1.75M
Avg Vol (10d)3.37M
Technical Indicators
RSI (14)61.1
MACD0.0173
MACD Signal0.0075
MACD Hist.+0.0098
BB Upper0.4802 USD
BB Middle0.3941 USD
BB Lower0.3079 USD
BB Width43.74%
ATR (14)0.0510 USD
Vol Ratio (20d)1.40x